• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

JAK 1 and 2 inhibitor superior to adalimumab in treatment of rheumatoid arthritis: The RA-BEAM trial

byMatthew GrowdonandShaidah Deghan, MSc. MD
February 16, 2017
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Baricitinib, an oral, once-daily inhibitor of JAK1 and JAK2, has shown promise in the treatment of rheumatoid arthritis (RA).

2. In this randomized controlled trial, baricitinib was superior to injectable adalimumab and placebo, in the amelioration of prespecified RA-related symptoms and radiologic outcomes after 12 weeks of follow-up.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The backbone of RA treatment consists of conventional synthetic disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and newer biologic DMARDs such as adalimumab, which targets tumor necrosis factor (TNF). RA-BEAM trial is a multicenter randomized controlled trial that compared baricitinib against placebo and adalimumab. Patients with active RA, received background therapy with methotrexate, and were randomized to receive placebo, baricitinib, or adalimumab. The primary outcome was 20% improvement according to the American College of Rheumatology (ACR20) criteria, which occurred significantly more often in the baricitinib group compared to placebo or adalimumab at week 12. There was also significantly reduced radiographic progression of joint damage at week 24 in the baricitinib group compared to placebo. Both baricitinib and adalimumab were associated with a greater number of adverse events, including infection, compared to placebo; baricitinib in particular was associated with neutropenia and lab abnormalities, such as transient increases in creatinine and cholesterol levels.

This drug-company sponsored trial provides promising evidence in support of a once-daily antirheumatic medication in comparison to accepted therapies including an every-other-week anti-TNF therapy and treatment with methotrexate.

Click to read the study, published today in NEJM

Relevant Reading: Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

RELATED REPORTS

Tofacitinib increases cardiovascular and cancer risk in rheumatoid arthritis

#VisualAbstract: Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection

Treatment of immune-mediated inflammatory diseases with tumor necrosis factor inhibitors is associated with lower COVID-19 hospitalization and death rates compared to other treatments

In-Depth [randomized controlled trial]: This study was conducted over 52 weeks at 281 centers in 26 countries. Participants had RA with an inadequate response to methotrexate patients. A total of 2949 patients were screened for this study and a total of 1305 were treated and qualified for analysis. The ACR20 criteria include a 20% or greater reduction in the number of tender and swollen joints and an improvement of 20% or more in at least three of the following measures: patient assessment of pain, patient global assessment of disease, physical function assessment, and the level of acute-phase reactant.

In the primary analysis, at week 12, the ACR20 response rate for baricitinib was 70% compared to 40% for placebo (p < 0.001). Additionally, baricitinib was found to be noninferior to adalimumab (61%) at week 12 for ACR20 response. In further testing with correction for multiple comparisons, baricitinib was superior to adalimumab for ACR20 response (p = 0.01). In secondary analyses, at week 24, both baricitinib and adalimumab achieved significantly reduced radiographic joint damage compared to placebo, with a suggestion of particular benefit in the adalimumab group.

In safety analyses, rates of serious infections were similar between all three groups (1%, 1%, and <1% respectively for placebo, baricitinib, and adalimumab. There were observed reductions in neutrophil counts, and increases in creatinine and liver enzymes (generally transient) in the baricitinib and adalimumab groups compared to placebo. LDL cholesterol levels increased with baricitinib to a greater extent than adalimumab.

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: JAK kinaserheumatoid arthritisTNF
Previous Post

Clinical decision tool may discriminate need for ICU in children with traumatic brain injury and intracranial injury

Next Post

Bariatric surgery superior to medical therapy for diabetes at five-years: The STAMPEDE trial

RelatedReports

2 Minute Medicine Rewind January 28, 2019
Cardiology

Tofacitinib increases cardiovascular and cancer risk in rheumatoid arthritis

February 2, 2022
#VisualAbstract: Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection
StudyGraphics

#VisualAbstract: Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection

January 5, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Treatment of immune-mediated inflammatory diseases with tumor necrosis factor inhibitors is associated with lower COVID-19 hospitalization and death rates compared to other treatments

October 20, 2021
#VisualAbstract Granuloma annulare was associated with increased risk of type 2 diabetes, hyperlipidemia, and certain autoimmune conditions
Chronic Disease

#VisualAbstract Granuloma annulare was associated with increased risk of type 2 diabetes, hyperlipidemia, and certain autoimmune conditions

June 18, 2021
Next Post
High incidence of foreskin morbidity in uncircumcised males

Bariatric surgery superior to medical therapy for diabetes at five-years: The STAMPEDE trial

Tonsillectomy may have short-term benefits in recurrent throat infection

AAP releases 2017 recommendations for preventive pediatric health care

AAP addresses neonatal pain prevention

Periviable infants are becoming more likely to survive without neurodevelopmental impairment

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.